SCHOTT Pharma AG & Co. KGaA

1SXP

Equity

ISIN DE000A3ENQ51 / Valor 128964250

Xetra (2026-06-26)

EUR 17.36+0.46%

SCHOTT Pharma AG & Co. KGaA
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

SCHOTT Pharma AG & Co. KGaA, a subsidiary of SCHOTT AG, specializes in the production of drug containment and delivery systems, including pharmaceutical syringes, cartridges, vials, and ampoules. With a global presence in 34 countries and 16 GMP-compliant manufacturing sites, the company produces over 13 billion drug containers annually, catering to the needs of the pharmaceutical industry. Employing more than 4,700 professionals across North America, Europe, Asia, and Latin America, SCHOTT Pharma collaborates with leading industry partners to ensure the safe, fast, and reliable delivery of medicines. The company operates under the ownership of the Carl Zeiss Foundation and is headquartered in Mainz, Germany. In the fiscal year 2021, SCHOTT Pharma contributed to SCHOTT AG's overall sales of 2.5 billion euros, leveraging its expertise in borosilicate glass and high-grade pharmaceutical COC polymer to meet diverse drug formulation requirements.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue and margins

Q2 2026 revenue: EUR 247.9m (‑1.5% vs Q2 2025). EBITDA: EUR 64.6m (‑10.1%); EBITDA margin: 26.0% vs 28.5% a year earlier (≈‑3.7 percentage points). EBIT: EUR 42.7m (‑19.0%); EBIT margin: 17.2% vs 20.9% in Q2 2025.

Profitability and EPS

Profit for the period: EUR 31.1m (‑18.7% YoY). Earnings per share: EUR 0.21 (‑16.0% YoY). Income tax expense moderated to EUR 9.2m from EUR 11.3m.

Cash flow and balance sheet

Operating cash flow improved to EUR 91.7m (Q2 2025: EUR 47.5m). Free cash flow rose to EUR 65.2m (Q2 2025: EUR 18.2m) after ongoing investing of EUR ‑26.5m. Net debt declined to EUR 110.0m (from EUR 122.2m), and the equity ratio increased to 58.6% (from 55.9%). Working capital was EUR 217.5m (21.9% of revenue).

Segment — Drug Containment Solutions (DCS)

DCS revenue grew to EUR 149.2m (+4.5% YoY; organic growth reported at +7.3%). Segment EBITDA: EUR 38.4m (+15.7%), EBITDA margin 25.7% (up from 23.2%). Segment EBIT: EUR 28.2m (+18.5%), EBIT margin 18.9% (improvement vs prior year).

Segment — Drug Delivery Systems (DDS)

DDS revenue declined to EUR 98.8m (‑9.5% YoY, largely organic). EBITDA fell to EUR 26.9m (‑28.0%), with EBITDA margin retreating to 27.2% from 34.2%. EBIT dropped sharply to EUR 15.4m (‑44.7%), EBIT margin 15.6% (vs 25.5% prior year).

H1 2026 snapshot

For the first half (Oct 1, 2025–Mar 31, 2026) revenue was EUR 488.1m (+1.0% YoY), EBITDA EUR 129.8m (‑0.6%), EBIT EUR 86.5m (‑6.9%), profit EUR 64.4m (‑5.4%), and free cash flow EUR 45.4m (vs EUR 22.3m prior H1).

Other operational notes

Share of High‑value Solutions (HVS) ~55% in Q2; headcount modestly up at 4,839 (from 4,811). Overall, the quarter shows resilient cash generation and balance‑sheet improvement, offset by margin pressure and weaker DDS performance.

Summarized from source with an LLMView Source

Key figures

-38.2%1Y

%3Y

%5Y

Performance

31.1%1Y

37.4%3Y

37.4%5Y

Volatility